Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma

Shinichiro Nakamura, Kazuhiro Nouso, Yuji Noguchi, Toshihiro Higashi, Toshiro Ono, Achim Jungbluth, Yao Tseng Chen, Lloyd J. Old, Eiichi Nakayama, Yasushi Shiratori

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background and Aim: The present study was designed to investigate the expression of and humoral response against NY-ESO-1 in patients with hepatocellular carcinoma and to analyze the relationship between expression of NY-ESO-1 mRNA and clinicopathological features. Methods: NY-ESO-1 mRNA and protein expression in surgically resected hepatocellular carcinoma specimens, adjacent non-cancerous liver and non-tumor bearing liver were examined by reverse transcription-polymerase chain reaction and immunohistochemical staining using a monoclonal antibody against NY-ESO-1 (ES121), respectively. The antibody response to NY-ESO-1 was examined by enzyme-linked immunosorbent assay using recombinant NY-ESO-1 protein. Results: NY-ESO-1 mRNA was detected in 18 of 41 (43.9%) hepatocellular carcinomas. No NY-ESO-1 mRNA was expressed in 41 paired non-cancerous specimens and 18 specimens histologically diagnosed as liver cirrhosis or chronic hepatitis. Immunohistochemistry revealed heterogeneous expression of NY-ESO-1 protein in three of 18 NY-ESO-1 mRNA-positive hepatocellular carcinomas. None of 23 NY-ESO-1 mRNA-negative hepatocellular carcinomas expressed NY-ESO-1 protein. Antibody against NY-ESO-1 protein was detected in two of 92 patients with hepatocellular carcinoma. Both of these patients had tumors invading main branches of the portal vein. Conclusions: The present study has demonstrated the expression of NY-ESO-1 mRNA in hepatocellular carcinoma and NY-ESO-1 antibody production in patients with advanced hepatocellular carcinoma. Although the enhancement of NY-ESO-1 protein expression and the activation of immune response of the patients with hepatocellular carcinoma are necessary, NY-ESO-1 has the potential to be a good target molecule for immunotherapy against advanced hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)1281-1285
Number of pages5
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume21
Issue number8
DOIs
Publication statusPublished - 2006

Fingerprint

Hepatocellular Carcinoma
Messenger RNA
Proteins
Antibody Formation
Liver
Chronic Hepatitis
Portal Vein
Liver Cirrhosis
Immunotherapy
Reverse Transcription
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Monoclonal Antibodies
Staining and Labeling
Polymerase Chain Reaction
Antibodies

Keywords

  • Cancer/ testis antigens
  • Human
  • Immunotherapy
  • Liver
  • Neoplasm

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Nakamura, S., Nouso, K., Noguchi, Y., Higashi, T., Ono, T., Jungbluth, A., ... Shiratori, Y. (2006). Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 21(8), 1281-1285. https://doi.org/10.1111/j.1440-1746.2006.04271.x

Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. / Nakamura, Shinichiro; Nouso, Kazuhiro; Noguchi, Yuji; Higashi, Toshihiro; Ono, Toshiro; Jungbluth, Achim; Chen, Yao Tseng; Old, Lloyd J.; Nakayama, Eiichi; Shiratori, Yasushi.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 21, No. 8, 2006, p. 1281-1285.

Research output: Contribution to journalArticle

Nakamura, S, Nouso, K, Noguchi, Y, Higashi, T, Ono, T, Jungbluth, A, Chen, YT, Old, LJ, Nakayama, E & Shiratori, Y 2006, 'Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma', Journal of Gastroenterology and Hepatology (Australia), vol. 21, no. 8, pp. 1281-1285. https://doi.org/10.1111/j.1440-1746.2006.04271.x
Nakamura, Shinichiro ; Nouso, Kazuhiro ; Noguchi, Yuji ; Higashi, Toshihiro ; Ono, Toshiro ; Jungbluth, Achim ; Chen, Yao Tseng ; Old, Lloyd J. ; Nakayama, Eiichi ; Shiratori, Yasushi. / Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. In: Journal of Gastroenterology and Hepatology (Australia). 2006 ; Vol. 21, No. 8. pp. 1281-1285.
@article{2e84341ed6744bd1a70007b175e38932,
title = "Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma",
abstract = "Background and Aim: The present study was designed to investigate the expression of and humoral response against NY-ESO-1 in patients with hepatocellular carcinoma and to analyze the relationship between expression of NY-ESO-1 mRNA and clinicopathological features. Methods: NY-ESO-1 mRNA and protein expression in surgically resected hepatocellular carcinoma specimens, adjacent non-cancerous liver and non-tumor bearing liver were examined by reverse transcription-polymerase chain reaction and immunohistochemical staining using a monoclonal antibody against NY-ESO-1 (ES121), respectively. The antibody response to NY-ESO-1 was examined by enzyme-linked immunosorbent assay using recombinant NY-ESO-1 protein. Results: NY-ESO-1 mRNA was detected in 18 of 41 (43.9{\%}) hepatocellular carcinomas. No NY-ESO-1 mRNA was expressed in 41 paired non-cancerous specimens and 18 specimens histologically diagnosed as liver cirrhosis or chronic hepatitis. Immunohistochemistry revealed heterogeneous expression of NY-ESO-1 protein in three of 18 NY-ESO-1 mRNA-positive hepatocellular carcinomas. None of 23 NY-ESO-1 mRNA-negative hepatocellular carcinomas expressed NY-ESO-1 protein. Antibody against NY-ESO-1 protein was detected in two of 92 patients with hepatocellular carcinoma. Both of these patients had tumors invading main branches of the portal vein. Conclusions: The present study has demonstrated the expression of NY-ESO-1 mRNA in hepatocellular carcinoma and NY-ESO-1 antibody production in patients with advanced hepatocellular carcinoma. Although the enhancement of NY-ESO-1 protein expression and the activation of immune response of the patients with hepatocellular carcinoma are necessary, NY-ESO-1 has the potential to be a good target molecule for immunotherapy against advanced hepatocellular carcinoma.",
keywords = "Cancer/ testis antigens, Human, Immunotherapy, Liver, Neoplasm",
author = "Shinichiro Nakamura and Kazuhiro Nouso and Yuji Noguchi and Toshihiro Higashi and Toshiro Ono and Achim Jungbluth and Chen, {Yao Tseng} and Old, {Lloyd J.} and Eiichi Nakayama and Yasushi Shiratori",
year = "2006",
doi = "10.1111/j.1440-1746.2006.04271.x",
language = "English",
volume = "21",
pages = "1281--1285",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma

AU - Nakamura, Shinichiro

AU - Nouso, Kazuhiro

AU - Noguchi, Yuji

AU - Higashi, Toshihiro

AU - Ono, Toshiro

AU - Jungbluth, Achim

AU - Chen, Yao Tseng

AU - Old, Lloyd J.

AU - Nakayama, Eiichi

AU - Shiratori, Yasushi

PY - 2006

Y1 - 2006

N2 - Background and Aim: The present study was designed to investigate the expression of and humoral response against NY-ESO-1 in patients with hepatocellular carcinoma and to analyze the relationship between expression of NY-ESO-1 mRNA and clinicopathological features. Methods: NY-ESO-1 mRNA and protein expression in surgically resected hepatocellular carcinoma specimens, adjacent non-cancerous liver and non-tumor bearing liver were examined by reverse transcription-polymerase chain reaction and immunohistochemical staining using a monoclonal antibody against NY-ESO-1 (ES121), respectively. The antibody response to NY-ESO-1 was examined by enzyme-linked immunosorbent assay using recombinant NY-ESO-1 protein. Results: NY-ESO-1 mRNA was detected in 18 of 41 (43.9%) hepatocellular carcinomas. No NY-ESO-1 mRNA was expressed in 41 paired non-cancerous specimens and 18 specimens histologically diagnosed as liver cirrhosis or chronic hepatitis. Immunohistochemistry revealed heterogeneous expression of NY-ESO-1 protein in three of 18 NY-ESO-1 mRNA-positive hepatocellular carcinomas. None of 23 NY-ESO-1 mRNA-negative hepatocellular carcinomas expressed NY-ESO-1 protein. Antibody against NY-ESO-1 protein was detected in two of 92 patients with hepatocellular carcinoma. Both of these patients had tumors invading main branches of the portal vein. Conclusions: The present study has demonstrated the expression of NY-ESO-1 mRNA in hepatocellular carcinoma and NY-ESO-1 antibody production in patients with advanced hepatocellular carcinoma. Although the enhancement of NY-ESO-1 protein expression and the activation of immune response of the patients with hepatocellular carcinoma are necessary, NY-ESO-1 has the potential to be a good target molecule for immunotherapy against advanced hepatocellular carcinoma.

AB - Background and Aim: The present study was designed to investigate the expression of and humoral response against NY-ESO-1 in patients with hepatocellular carcinoma and to analyze the relationship between expression of NY-ESO-1 mRNA and clinicopathological features. Methods: NY-ESO-1 mRNA and protein expression in surgically resected hepatocellular carcinoma specimens, adjacent non-cancerous liver and non-tumor bearing liver were examined by reverse transcription-polymerase chain reaction and immunohistochemical staining using a monoclonal antibody against NY-ESO-1 (ES121), respectively. The antibody response to NY-ESO-1 was examined by enzyme-linked immunosorbent assay using recombinant NY-ESO-1 protein. Results: NY-ESO-1 mRNA was detected in 18 of 41 (43.9%) hepatocellular carcinomas. No NY-ESO-1 mRNA was expressed in 41 paired non-cancerous specimens and 18 specimens histologically diagnosed as liver cirrhosis or chronic hepatitis. Immunohistochemistry revealed heterogeneous expression of NY-ESO-1 protein in three of 18 NY-ESO-1 mRNA-positive hepatocellular carcinomas. None of 23 NY-ESO-1 mRNA-negative hepatocellular carcinomas expressed NY-ESO-1 protein. Antibody against NY-ESO-1 protein was detected in two of 92 patients with hepatocellular carcinoma. Both of these patients had tumors invading main branches of the portal vein. Conclusions: The present study has demonstrated the expression of NY-ESO-1 mRNA in hepatocellular carcinoma and NY-ESO-1 antibody production in patients with advanced hepatocellular carcinoma. Although the enhancement of NY-ESO-1 protein expression and the activation of immune response of the patients with hepatocellular carcinoma are necessary, NY-ESO-1 has the potential to be a good target molecule for immunotherapy against advanced hepatocellular carcinoma.

KW - Cancer/ testis antigens

KW - Human

KW - Immunotherapy

KW - Liver

KW - Neoplasm

UR - http://www.scopus.com/inward/record.url?scp=33745839341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745839341&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2006.04271.x

DO - 10.1111/j.1440-1746.2006.04271.x

M3 - Article

C2 - 16872310

AN - SCOPUS:33745839341

VL - 21

SP - 1281

EP - 1285

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 8

ER -